Mir-155 as a diagnostic and prognostic marker in hematological and solid malignancies

Neoplasma

Volumn 61, Issue 3, 2014, Pages 241-251

  Jurkovicova, D ^a   Magyerkova, M ^a   Kulcsar, L ^a   Krivjanska, M ^a   Krivjansky, V ^a   Gibadulinova, A ^b   Oveckova, I ^b   Chovanec, M ^a,c  

^a KRD Molecular Technologies Ltd   (Slovakia)

^b INSTITUTE OF VIROLOGY   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Carcinogenesis; Diagnosis; Gene expression regulation; Mir 155; Prognosis; Therapy

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; MESSENGER RNA; MICRORNA 155; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COLORECTAL CARCINOMA; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; PANCREAS CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902329035     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_032     Document Type: Review

References (106)

1. HONG J, ZHANG H, KAWASE-KOGA Y, SUN T. MicroRNA function is required for neurite outgrowth of mature neurons in the mouse postnatal cerebral cortex. Front Cell Neurosci 2013; 7: 151. http://dx.doi.org/10.3389/fncel.2013.00151
2. COSTINEAN S, ZANESI N, PEKARSKY Y, TILI E, VOLINIA S et al. Pre-B cell proliferation and lymphoblastic leukemia/ high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-7029. http://dx.doi.org/10.1073/pnas.0602266103
3. HATFIELD S, RUOHOLA-BAKER H. microRNA and stem cell function. Cell Tissue Res 2008; 331: 57-66. http://dx.doi.org/10.1007/s00441-007-0530-3
4. CHEN Y, STALLINGS RL. DifferentialpatternsofmicroRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007; 67: 976-983. http://dx.doi.org/10.1158/0008-5472.CAN-06-3667
5. BALTIMORE D, BOLDIN MP, O'CONNELL RM, RAO DS, TAGANOV KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9: 839-845. http://dx.doi.org/10.1038/ni.f.209
6. TRIBOULET R, MARI B, LIN YL, CHABLE-BESSIA C, BENNASSER Y et al. Supression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007; 315: 1579-1582. http://dx.doi.org/10.1126/science.1136319
7. KASINSKI AL, SLACK FJ. Epigenetics and genetics. MicroR-NAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864. http://dx.doi.org/10.1038/nrc3166
8. ALEVIZOS I, ILLEI GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 2010; 6: 391-398. http://dx.doi.org/10.1038/nrrheum.2010.81
9. BARTEL DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233. http://dx.doi.org/10.1016/j.cell.2009.01.002
10. KRUTZFELDT J, STOFFEL M. MicroRNAs: a new class of regulatory genes affecting metabolism. Cell Metab 2006; 4: 9-12. http://dx.doi.org/10.1016/j.cmet.2006.05.009
11. FRIEDMAN RC, FARH KK, BURGE CB, BARTEL DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 1: 92-105.
12. DOMBKOWSKI AA, SULTANA Z, CRAIG DB, JAMIL H. In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis. Cancer Inform 2011; 10: 13-29. http://dx.doi.org/10.4137/CIN.S6631
13. FORREST AR, KANAMORI-KATAYAMA M, TOMARU Y, LASSMANN T, NINOMIYA N et al. Induction of micro-RNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010; 24: 460-466. http://dx.doi.org/10.1038/leu.2009.246
14. KROL J, LOEDIGE I, FILIPOWICZ W. Te widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
15. FABIAN MR, SONENBERG N. TemechanicsofmiRNAme-diated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586-593. http://dx.doi.org/10.1038/nsmb.2296
16. CHENDRIMADA TP, GREGORY RI, KUMARASWAMY E, NORMAN J, COOCH N et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-744. http://dx.doi.org/10.1038/nature03868
17. FILIPOWICZ W, BHATTACHARYYA SN, SONENBERG N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 2: 102-114. http://dx.doi.org/10.1038/nrg2290
18. GRIFFITHS-JONES S. Te microRNA registry. Nucleic Acids Res 2004; 32: D109-D111. http://dx.doi.org/10.1093/nar/gkh023
19. RUEGGER S, GROSSHANS H. MicroRNA turnover: when, how, and why. Trends Biochem Sci 2012; 37: 436-446. http://dx.doi.org/10.1016/j.tibs.2012.07.002
20. GRIMSON A, FARH KKH, JOHNSTON WK, GARRETT-ENGELE P, LIM LP et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91-105. http://dx.doi.org/10.1016/j.molcel.2007.06.017
21. CHENDRIMADA TP, KENNETH JF, XINJUN J, BAILLAT D, GREGORY RI et al. MicroRNA silencing through RISC recruitment of eIF6. Nature 2007; 447: 823-828. http://dx.doi.org/10.1038/nature05841
22. GUO H, INGOLIA NT, WEISSMAN JS, BARTEL DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840. http://dx.doi.org/10.1038/nature09267
23. TAM W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 2001; 274: 157-167. http://dx.doi.org/10.1016/S0378-1119(01)00612-6
24. SHIN C. Cleavage of the star strand facilitates assembly of some microRNAs into Ago2-containing silencing complexes in mammals. Mol Cell 2008; 26: 308-313.
25. PACKER AN, XING Y, HARPER SQ, JONES L, DAVIDSON BL. Te bifunctional microRNA, miR-9/miR-9*, regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci 2008; 28: 14341-14346. http://dx.doi.org/10.1523/JNEUROSCI.2390-08.2008
26. YANG JS, PHILLIPS MD, BETEL D, MU P, VENTURA A et al. Widespread regulatory activity of vertebrate microRNA* species. RNA 2011; 17: 312-326. http://dx.doi.org/10.1261/rna.2537911
27. ELTONT S, SANSOM SE, MARTIN MM. Trisomy-21 gene dosage overexpression of miRNAs results in the haploinsuf-ficiency of specific target proteins. RNA Biol 2010; 7: 540-547. http://dx.doi.org/10.4161/rna.7.5.12685
28. TARASSISHIN L, LOUDIG O, BAUMAN A, SHAFIT-ZA-GARDO B, SUH HS et al. Interferon regulatory factor 3 inhibits astrocyte inflammatorygene expression through suppression of the proinflammatorymiR-155 and miR-155*. Glia 2011; 59: 1911-1922. http://dx.doi.org/10.1002/glia.21233
29. ZHOU H, HUANG X, CUI H, LUO X, TANG Y et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010; 116: 5885-5894. http://dx.doi.org/10.1182/blood-2010-04-280156
30. Mao C P, HE L, TSAI YC, PENG S, KANG TH et al. In vivo microRNA-155 expression influences antigen-specificT cell-mediated immune responses generated by DNA vaccination. Cell Biosci 2011; 1: 3. http://dx.doi.org/10.1186/2045-3701-1-3
31. O'CONNELL RM, TAGANOV KD, BOLDIN MP, CHENG G, BALTIMORE D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci US A 2007; 104: 1604-1609. http://dx.doi.org/10.1073/pnas.0610731104
32. GEORGANTAS III RW, HILDRETH R, MORISOT S, ALDER J, LIU C et al. CD34 + hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-2755. http://dx.doi.org/10.1073/pnas.0610983104
33. MASAKI S, OHTSUKA R, ABE Y, MUTA K, UMEMURA T. Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun 2007; 364: 509-514. http://dx.doi.org/10.1016/j.bbrc.2007.10.077
34. LANDGRAF P, RUSU M, SHERIDAN R, SEWER A, IOVINO N et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414. http://dx.doi.org/10.1016/j.cell.2007.04.040
35. MARTIN MM, LEE EJ, BUCKENBERGER JA, SCHMITT-GEN TD, ELTON TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 28: 18277-18284. http://dx.doi.org/10.1074/jbc. M601496200
36. STANCZYK J, PEDRIOLI DML, BRENTANO F, SANCHEZ-PERNAUTE O, KOLLING C et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58: 1001-1009. http://dx.doi.org/10.1002/art.23386
37. KONG W, YANG H, HE L, ZHAO JJ, COPPOLA D et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28: 6773-84. http://dx.doi.org/10.1128/MCB.00941-08
38. YIN Q, MCBRIDE J, FEWELL C, LACEY M, WANG X et al. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol 2008; 82: 5295-5306. http://dx.doi.org/10.1128/JVI.02380-07
39. JIANG J, LEE EJ, SCHMITTGEN TD. Increased expression of microRNA-155 in Epstein-Barr virus transformed lym-phoblastoid cell lines. Genes Chromosomes Cancer 2006; 45: 103-106. http://dx.doi.org/10.1002/gcc.20264
40. KLUIVER J, HARALAMBIEVA E, DE JONG D, BLOKZIJL T, JACOBS S et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 2006; 45: 147-153. http://dx.doi.org/10.1002/gcc.20273
41. LINNSTAEDT SD, GOTTWEIN E, SKALSKY RL, LUFTIG MA, CULLEN BR. Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Ep-stein-Barr virus. J Virol 2010; 84: 11670-11678. http://dx.doi.org/10.1128/JVI.01248-10
42. GATTO G, ROSSI A, ROSSI D, KROENING S, BONATTI S et al. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res 2008; 36: 6608-6619. http://dx.doi.org/10.1093/nar/gkn666
43. WANG L, TOOMEY NL, DIAZ LA, WALKER G, RAMOS JC et al. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression. J Virol 2011; 85: 8328-8337. http://dx.doi.org/10.1128/JVI.00570-11
44. CREMER TJ, RAVNEBERG DH, CLAY CD, PIPER-HUNTER MG, MARSH CB et al. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatorycytokine response. PLoSOne 2009; 4: e8508 http://dx.doi.org/10.1371/journal.pone.0008508
45. O'CONNELL RM, CHAUDHURI AA, RAO DS, BALTIMORE D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U SA 2009; 106: 7113-7118. http://dx.doi.org/10.1073/pnas.0902636106
46. VARGOVA K, CURIK N, BURDA P, BASOVA P, KULVAIT V et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011; 117: 3816-3825. http://dx.doi.org/10.1182/blood-2010-05-285064
47. EIS PS, TAM W, SUN L, CHADBURN A, LI Z et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627-3632. http://dx.doi.org/10.1073/pnas.0500613102
48. FULCI V, CHIARETTI S, GOLDONI M, AZZALIN G, CARUCCI N et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109: 4944-4951. http://dx.doi.org/10.1182/blood-2006-12-062398
49. KLUIVER J, POPPEMA S, DE JONG D, BLOKZIJL T, HARMS G et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207: 243-249. http://dx.doi.org/10.1002/path.1825
50. O'CONNELL RM, RAO DS, CHAUDHURI AA, BOLDIN MP, TAGANOV KD et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585-594. http://dx.doi.org/10.1084/jem.20072108
51. RAMKISSOON SH, MAINWARINGC LA, OGASA-WARAC Y, KEYVANFARC K, MCCOY JR CJP et al. Hematopoieticspecific microRNA expression in human cells. Leuk Res 2006; 30: 643-647. http://dx.doi.org/10.1016/j.leukres.2005.09.001
52. THOMPSON RC, HERSCOVITCH M, ZHAO I, FORD TJ, GILMORE TD. NF-kappaB down-regulatesexpressionofheB-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem 201; 286: 1675-1682.
53. VAN DEN BERG A, KROESEN BJ, KOOISTRA K, DE JONG D, BRIGGS J et al. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosom Cancer 2003; 37: 20-28. http://dx.doi.org/10.1002/gcc.10186
54. RAHADIANI N, TAKAKUWA T, TRESNASARI K, MORII E, AOZASA K. Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun 2008; 377: 579-83. http://dx.doi.org/10.1016/j.bbrc.2008.10.007
55. CALIN GA, CROCE CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 2009; 114: 4761-4770. http://dx.doi.org/10.1182/blood-2009-07-192740
56. MRAZ M, POSPISILOVA S, MALINOVA K, SLAPAK I, MAYER J. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009; 50: 506-509. http://dx.doi.org/10.1080/10428190902763517
57. KAUFMAN M, RUBIN J, RAI K. Diagnosing and treating chronic lymphocytic leukemia in 2009. Oncology 2009; 23: 1030-1037.
58. OVCHARENKO D, KELNAR K, JOHNSON C, LENG N, BROWN D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 2007; 67: 10782-10788. http://dx.doi.org/10.1158/0008-5472.CAN-07-1484
59. GIRONELLA M, SEUX M, XIE MJ, CANO C, TOMASINI R et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci US A 2007; 104: 16170-16175. http://dx.doi.org/10.1073/pnas.0703942104
60. DORSETT Y, MCBRIDE KM, JANKOVIC M, GAZUMYAN A, THAI TH et al. MicroRNA-155 suppresses activation-induced cytidinedeaminase-mediated Myc-Igh translocation. Immunity 2008; 28: 630-638. http://dx.doi.org/10.1016/j.immuni.2008.04.002
61. MUTO T, OKAZAKI IM, YAMADA S, TANAKA Y, K-INOSHITA K. Negative regulation of activation-induced cytidinedeaminase in B cells. Proc Natl Acad Sci USA 2006; 103: 2752-2757. http://dx.doi.org/10.1073/pnas.0510970103
62. DE YEBENES VG, BELVER L, PISANO DG, GONZALEZ S, VILLASANTE A et al. miR-181b negatively regulates activation-induced cytidinedeaminase in B cells. J Exp Med 2008; 205: 2199-2206. http://dx.doi.org/10.1084/jem.20080579
63. ALENCAR AJ, MALUMBRES R, KOZLOSKI GA, ADVANI R, TALREJA N et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17: 4125-4135. http://dx.doi.org/10.1158/1078-0432.CCR-11-0224
64. RAI D, KIM SW, MCKELLER MR, DAHIA PL, AGUIAR RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010; 107: 3111-3116. http://dx.doi.org/10.1073/pnas.0910667107
65. HUANG X, SHEN Y, LIU M, BI C, JIANG C. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol 2012; 181: 26-33. http://dx.doi.org/10.1016/j.ajpath.2012.03.013
66. PEDERSEN IM, OTERO D, KAO E, MILETIC AV, HOTHER C. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med 2009; 1: 288-295. http://dx.doi.org/10.1002/emmm.200900028
67. COMPAGNO M, LIM WK, GRUNN A, NANDULA SV, BRAHMACHARY M et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721. http://dx.doi.org/10.1038/nature07968
68. HUI ABY, SHI W, BOUTROS PC, MILLER N, PINTILIE M et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009: 89: 597-606. http://dx.doi.org/10.1038/labinvest.2009.12
69. KONG W, HE L, COPPOLA M, GUO J, ESPOSITO NN et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869-17879. http://dx.doi.org/10.1074/jbc. M110.101055
70. VOLINIA S, CALIN GA, LIU CG, AMBS S, CIMMINO A et al. A microRNA expression signature of human solid tumors defines cancer gene targets. ProcNatl Acad Sci USA 2006; 103: 2257-2261. http://dx.doi.org/10.1073/pnas.0510565103
71. LEE EJ, GUSEV Y, JIANG J, NUOVO GJ, LERNER MR et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J Cancer 2007; 120: 1046-1054.
72. SZAFRANSKA AE, DAVISON TS, JOHN J, CANNON T, SIPOS B et al. MicroRNA expression alterations are linked to tumorigenesis and nonneoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452. http://dx.doi.org/10.1038/sj.onc.1210228
73. WANG X, TANG S, LE SY, LU R, RADER JS et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008; 3: 2557. http://dx.doi.org/10.1371/journal.pone.0002557
74. JAY C, NEMUNAITIS J, CHEN P, FULGHAM P, TONG AW. MiRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007; 26: 293-300. http://dx.doi.org/10.1089/dna.2006.0554
75. NIKIFOROVA MN, TSENG GC, STEWARD D, DIORIO D, NIKIFOROV YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008; 93: 1600-1608. http://dx.doi.org/10.1210/jc.2007-2696
76. MATTISKE S, SUETANI RJ, NEILSEN PM, CALLEN DF. Te OncogenicRoleofmiR-155inBreast Cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1236-1243. http://dx.doi.org/10.1158/1055-9965.EPI-12-0173
77. CHANG S, WANG RH, AKAGI K, KIM KA, MARTIN BK et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011; 17: 1275-1282. http://dx.doi.org/10.1038/nm.2459
78. YARDEN RI, BRODY LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 1999; 96: 4983-4988. http://dx.doi.org/10.1073/pnas.96.9.4983
79. NEILSEN PM, NOLL JE, MATTISKE S, BRACKEN CP, GREGORY PA et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2012a; 32: 2992-3000.
80. JIANG S, ZHANG HW, LU MH, HE XH, LI Y et al. Mi-croRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70: 3119-3127. http://dx.doi.org/10.1158/0008-5472.CAN-09-4250
81. ADORNO M, CORDENONSI M, MONTAGNER M, DU-PONT S, WONG C et al. A mutant-p53/Smad complex opposes p63 to empower TGF2-induced metastasis. Cell 2009; 137: 87-98. http://dx.doi.org/10.1016/j.cell.2009.01.039
82. MULLER PAJ, CASWELL PT, DOYLE B, IWANICKI MP, TAN EH et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341. http://dx.doi.org/10.1016/j.cell.2009.11.026
83. MCINNES N, SADLON TJ, BROWN CY, PEDERSON S, BEYER M et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012; 31: 1045-1054. http://dx.doi.org/10.1038/onc.2011.293
84. LADOIRE S, ARNOULD L, MIGNOT G, COUDERT B, REBE C et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011; 125: 65-72. http://dx.doi.org/10.1007/s10549-010-0831-1
85. ZUO T, LIU R, ZHANG H, CHANG X, LIU Y et al. FOXP3 is a novel transcriptional repressor for the breast cancer on-cogene SKP2. J Clin Invest 2007; 117: 3765-3773.
86. WU WK, LAW PT, LEE CW, CHO CH, FAN D. Micro-RNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011; 32: 247-253. http://dx.doi.org/10.1093/carcin/bgq243
87. FALTEJSKOVA P, SVOBODA M, SRUTOVA K, MLCOCHOVA J, BESSE A et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012; 16: 2655-2666. http://dx.doi.org/10.1111/j.1582-4934.2012.01579.x
88. SHIBUYA H, IINUMA H, SHIMADA R, HORIUCHI A, WATANABE T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-20. http://dx.doi.org/10.1159/000323283
89. SINGH AK, PANDEY R, GILL K, SINGH R, SARAYA A. p38β MAP kinase as a therapeutic target for pancreatic cancer. Chem Biol Drug Des 2012; 80: 266-273. http://dx.doi.org/10.1111/j.1747-0285.2012.01395.x
90. BUSHATI N, COHEN SM. MicroRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205. http://dx.doi.org/10.1146/an-nurev.cellbio.23.090506.123406
91. KUHN DE, MARTINE MM, FELDMANC DS, TERRY JR. AV, NUOVO GJ et al. Experimental validation of miRNA targets. Methods 2008; 44: 47-54. http://dx.doi.org/10.1016/j.ymeth.2007.09.005
92. NIELSEN BS. MicroRNA in situ hybridization. Methods Mol Biol 2012b; 822: 67-84.
93. ELTON TS, SELEMON H, ELTON SM, PARINANDI NL. Regulation of the MIR155 host gene in physiological and pathological processes. Gene 2012; S0378-S1119: 01512-0.
94. QI J, WANG J, KATAYAMA H, SEN S, LIU SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013; 60: 135-142. http://dx.doi.org/10.4149/neo_2013_018
95. SLABY O, LAKOMY R, FADRUS P, HRSTKA R, KREN L et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010; 57: 264-269. http://dx.doi.org/10.4149/neo_2010_03_264
96. HE J, ZHANG F, WU Y, ZHANG W, ZHU X et al. Prognostic role of microRNA-155 in various carcinomas: results from a meta-analysis. Dis Markers 2013; 34: 379-386. http://dx.doi.org/10.1155/2013/856750
97. VAN ROOIJ E, PURCELL AL, LEVIN AA. Developing micro-RNA therapeutics. Circ Res 2012; 110: 496-507. http://dx.doi.org/10.1161/CIRCRESAHA.111.247916
98. BABARI A, CHENGB CJ, BOOTHD CJ, LIANGA X, WEI-DHAASE JB et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lym-phoma. Proc Natl Acad Sci USA 2012; 109: E1695-E1704. http://dx.doi.org/10.1073/pnas.1201516109
99. CORSTENM F, PAPAGEORGIOU A, VERHESEN W, CARAI P, LINDOW M et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 2012; 11: 415-425. http://dx.doi.org/10.1161/CIRCRESAHA.112.267443
100. FABANI MM, ABREU-GOODGER C, WILLIAMS D, LYONS PA, TORRES AG et al. Efficient inhibitionofmiR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 2010; 38: 4466-4475. http://dx.doi.org/10.1093/nar/gkq160
101. KUHN DE, NUOVO GJ, TERRY JR. AV, MARTIN MM, MALANA GE et al. Chromosome 21-derived miRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem 2010; 285: 1529-1543. http://dx.doi.org/10.1074/jbc.M109.033407
102. MURUGAIYAN G, BEYNON V, MITTAL A, JOLLER N, WEINER HL. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2011; 187: 2213-2221. http://dx.doi.org/10.4049/jimmunol.1003952
103. RANGANATHAN P, HEAPHY CEA, COSTINEAN S, STAUFFER N, NA C et al. Regulation of acute graf-versus-host disease by microRNA-155. Blood 2012; 119: 4786-4797. http://dx.doi.org/10.1182/blood-2011-10-387522
104. WORM J, STENVANG J, PETRI A, FREDERIKSEN KS, OBAD S et al. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucl Acids Res 2009; 37: 5784-5792. http://dx.doi.org/10.1093/nar/gkp577
105. ZHANG Y, ROCCARO AM, ROMBAOA C, FLORES L, OBAD S et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012; 120: 1678-1686. http://dx.doi.org/10.1182/blood-2012-02-410647
106. ZHANG H, SHYKIND B, SUN T. Approaches to manipulating microRNAs in neurogenesis. Front Neurosci 2013; 6: 196. http://dx.doi.org/10.3389/fnins.2012.00196